Idiopathic asthenospermia urine biomarker
Through metabolomics research, 4'-phosphoubenylcysteine, 11-hydroxy-14,15-epoxyeicosatotrienoic acid, and 15-keto-prostaglandin F2a were discovered and validated as urinary biomarkers, solving the problem of early diagnosis of idiopathic asthenospermia and achieving highly sensitive and specific urine detection, which is suitable for the early diagnosis and treatment of idiopathic asthenospermia.
Patent Information
- Application Number
- CN202411006577.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-25
- Publication Date
- 2024-11-08
AI Technical Summary
Current technologies have failed to effectively utilize metabolomics methods to discover urinary biomarkers for the early diagnosis of male idiopathic asthenospermia, resulting in an inability to provide targeted diagnosis and treatment for patients in clinical practice.
Through metabolomics studies, three urinary biomarkers—4'-phosphoubenylcysteine, 11-hydroxy-14,15-epoxyeicosatotrienoic acid, and 15-keto-prostaglandin F2a—were discovered and validated for the early diagnosis of idiopathic asthenospermia, and corresponding detection methods and kits were developed.
It provides highly sensitive and specific urine biomarkers for the early diagnosis of idiopathic asthenospermia. The detection method is non-invasive, rapid, and can accurately reflect the differences in male metabolic profiles with high specificity.
Smart Images

Figure CN118914393A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to a urine biomarker for idiopathic asthenospermia. Background Art
[0002] The clinical manifestations of male infertility are quite diverse and the corresponding pathogenesis is very complex. Among them, asthenospermia is a major cause of male infertility. Asthenospermia can be divided into mild, moderate and severe according to the degree of its occurrence. Asthenospermia of different severity can cause up to 80% of male infertility cases. Idiopathic asthenospermia (IAS) is a special clinical phenotype group among asthenospermia patients. Its clinical manifestations are simple low sperm motility, while other clinical index parameters such as genetic factors, organic diseases of the reproductive system, reproductive endocrine, and semen concentration are consistent with normal men. The diagnostic criteria for idiopathic asthenospermia are that the male undergoes routine semen analysis for 2 or more times according to the "WHO Laboratory Manual for the Examination and Processing of Human Semen, Fifth Edition", with a percentage of forward-moving sperm of less than 32% and a sperm concentration of more than 15×10 6 / mL, the percentage of normal sperm morphology> 4%, and excluding men with systemic diseases such as azoospermia, reproductive system anatomy abnormalities, varicocele, infection, trauma surgery, tumors, endocrine, hypertension and obesity, as well as men with abnormal karyotype and Y chromosome microdeletion. However, the regulatory mechanism of low sperm motility in IAS patients is still unclear, and the cause of IAS is unknown, which makes it impossible to diagnose and treat patients in a targeted manner in clinical practice.
[0003] Metabolomics (metabonomics / metabolomics) is a research method that follows the research ideas of genomics and proteomics, quantitatively analyzes all metabolites in organisms, and seeks the relative relationship between metabolites and physiological and pathological changes. It is an integral part of systems biology. Genomics and proteomics explore the activities of life from the gene and protein levels respectively, but in fact many life activities in cells occur at the metabolite level, such as cell signaling, energy transfer, and intercellular communication, which are all regulated by metabolites. Metabolites reflect the environment in which cells are located more, which is closely related to the nutritional status of cells, the effects of drugs and environmental pollutants, and other external factors. The main technical means of metabolomics are nuclear magnetic resonance (NMR), mass spectrometry (MS), chromatography (HPLC, GC) and chromatography-mass spectrometry. By detecting the NMR spectra of a series of samples and combining them with pattern recognition methods, the pathophysiological state of the organism can be determined, and it is possible to find related biomarkers. Therefore, through in-depth research on the body's metabolites, it is possible to determine whether the body is in a normal state. However, there are currently no reports on the use of metabolomics to search for biomarkers for the early diagnosis of male idiopathic asthenospermia, and the currently reported urine biomarkers that can be used for diagnosis do not involve idiopathic asthenospermia or sperm motility. Summary of the invention
[0004] The technical problem to be solved by the present invention is to provide an application of a urine biomarker for idiopathic asthenospermia and a detection method thereof.
[0005] In order to solve the above technical problems, as the first aspect of the present invention, the present invention provides a urine biomarker for idiopathic asthenospermia, which is one or more of 4'-phosphopantothenoylcysteine (CAS: 7196-09-0), 11-hydroxy-14,15-epoxyeicosatrienoic acid (11H-14,15-EETA, CAS: 219535-29-2), and 15-keto-prostaglandin F2a (CAS: 35850-13-6).
[0006] The present invention is based on metabolomics, studies and analyzes the characteristic differential metabolites between normal men and patients with idiopathic asthenospermia, and finally obtains urine biomarkers for early diagnosis of idiopathic asthenospermia: 4'-phosphopantothenoylcysteine (CAS: 7196-09-0), 11-hydroxy-14,15-epoxyeicosatrienoic acid (11H-14,15-EETA, CAS: 219535-29-2), 15-keto-prostaglandin F2a (CAS: 35850-13-6). The sensitivity and specificity of these markers are greater than 0.9, and the area under the curve (AUC) is greater than or equal to 0.9, indicating that these three indicators have good predictive properties and can be used for the early diagnosis of idiopathic asthenospermia.
[0007] As a second aspect of the present invention, the present invention provides the use of idiopathic asthenospermia urine biomarkers in the preparation of a kit for detecting idiopathic asthenospermia, wherein the idiopathic asthenospermia urine biomarkers are one or more of 4'-phosphopantenylated cysteine, 11-hydroxy-14,15-epoxyeicosatrienoic acid, and 15-keto-prostaglandin F2a.
[0008] As the third aspect of the present invention, the present invention provides the use of a reagent for detecting urine biomarkers of idiopathic asthenospermia in the preparation of a kit for detecting idiopathic asthenospermia, wherein the urine biomarkers of idiopathic asthenospermia are one or more of 4'-phosphopantenylated cysteine, 11-hydroxy-14,15-epoxyeicosatrienoic acid, and 15-keto-prostaglandin F2a.
[0009] As the fourth aspect of the present invention, the present invention provides the use of idiopathic asthenospermia urine biomarkers in the preparation or screening of drugs for the treatment of idiopathic asthenospermia, wherein the idiopathic asthenospermia urine biomarkers are one or more of 4'-phosphopantenylated cysteine, 11-hydroxy-14,15-epoxyeicosatrienoic acid, and 15-keto-prostaglandin F2a.
[0010] As a fifth aspect of the present invention, the present invention provides a kit for detecting idiopathic asthenospermia, which includes a reagent for detecting urine biomarkers of idiopathic asthenospermia, wherein the urine biomarkers of idiopathic asthenospermia are one or more of 4'-phosphopantenylic cysteine, 11-hydroxy-14,15-epoxyeicosatrienoic acid, and 15-keto-prostaglandin F2a. The kit can determine whether a subject suffers from idiopathic asthenospermia by detecting the concentration of the above one or more markers.
[0011] As a fifth aspect of the present invention, the present invention also provides a method for detecting urine biomarkers of idiopathic asthenospermia, comprising the following steps:
[0012] The urine to be tested is extracted with an extraction solvent to obtain a test solution;
[0013] The test solution is measured by liquid chromatography-mass spectrometry to obtain;
[0014] Wherein, the extraction solvent is a mixture of acetonitrile and methanol, and the volume ratio of acetonitrile to methanol is 1:1 to 3:3;
[0015] The chromatographic conditions of the liquid chromatography-mass spectrometry instrument include: a mixed solution of acetonitrile and water as mobile phase A, a mixture of acetonitrile, isopropanol and water as mobile phase B; the volume ratio of acetonitrile to water in mobile phase A is 90:10 to 99:1, and the volume ratio of acetonitrile, isopropanol and water in mobile phase B is 40:40:3 to 50:50:8;
[0016] The mass spectrometry conditions of the liquid chromatography-mass spectrometry instrument include a mass scanning range of m / z 70 to 1050;
[0017] Wherein, the idiopathic asthenospermia urine biomarker is one or more of 4'-phosphopantenylated cysteine, 11-hydroxy-14,15-epoxyeicosatrienoic acid, and 15-keto-prostaglandin F2a.
[0018] As an improvement of the above technical solution, in the step of extracting the urine to be tested with an extraction solvent to obtain a test solution, the urine to be tested and the extraction solvent are mixed in a volume ratio of 1:3 to 1:5, and ultrasonic extraction is performed at a frequency of 20kHz to 50kHz for 10min to 60min at 3°C to 10°C, and then the mixture is allowed to stand at -30°C to -10°C for 10min to 50min, and the supernatant is taken after centrifugation, and dried to obtain a solid phase, and the solid phase is dissolved with a complex solution, and ultrasonic extraction is performed at a frequency of 20kHz to 50kHz for 2min to 10min at 3°C to 10°C, and the supernatant is taken after centrifugation to obtain the test solution;
[0019] The extraction solvent contains 0.01 mg / mL to 0.1 mg / mL of L-2-chlorophenylalanine; the reconstitution solution is a mixture of acetonitrile and methanol, and the volume ratio of acetonitrile to methanol is 1:1 to 3:3.
[0020] As an improvement of the above technical solution, the volume ratio of acetonitrile to water in the mobile phase A is 95:5, and the mobile phase A contains 0.1 vol% formic acid;
[0021] The volume ratio of acetonitrile, isopropanol and water in the mobile phase B is 47.5:47.5:5; and the mobile phase B contains 0.1 vol% formic acid.
[0022] As an improvement of the above technical solution, the chromatographic conditions of the liquid chromatography-mass spectrometry instrument also include:
[0023] The chromatographic column of the chromatographic-mass spectrometer uses octadecyl bonded silica gel as a filler, and its column length is 50 mm to 250 mm, the column diameter is 1 mm to 3 mm, and the particle size of the filler is 1.7 μm to 3 μm;
[0024] The injection volume is 1 μL to 5 μL, the flow rate is 0.1 mL / min to 1 mL / min, and the column temperature is 30°C to 45°C.
[0025] As an improvement of the above technical solution, the chromatographic conditions of the liquid chromatography-mass spectrometry instrument also include:
[0026] Positive and negative ion scanning modes were adopted, with a sheath gas flow rate of 30psi~80psi, an auxiliary gas flow rate of 10psi~20psi, an auxiliary gas heating temperature of 400℃~450℃, an ion spray voltage of 3000V~4000V in positive ion mode, an ion spray voltage of -4000V~-3000V in negative ion mode, an ion transfer tube temperature of 320℃~350℃, a normalized collision energy of 20-40-60V cyclic collision energy, a primary mass spectrometer resolution of 50000~70000, a secondary mass spectrometer resolution of 6000~8000, and DDA mode was adopted to collect data.
[0027] As an improvement of the above technical solution, the chromatographic conditions of the liquid chromatography-mass spectrometry instrument also include:
[0028] The chromatographic column of the chromatography-mass spectrometry instrument is a Waters Xselect HSS T3 chromatographic column, with a column length of 100 mm, a column diameter of 2.1 mm, and a particle size of the filling phase of 1.8 μm;
[0029] The injection volume was 3 μL, the flow rate was 0.4 mL / min, and the column temperature was 40 °C;
[0030] The chromatographic conditions of the liquid chromatography-mass spectrometer also include:
[0031] Positive and negative ion scanning modes were adopted, with a sheath gas flow rate of 50 psi, an auxiliary gas flow rate of 13 psi, an auxiliary gas heating temperature of 425°C, an ion spray voltage of 3500 V in positive ion mode, an ion spray voltage of -3500 V in negative ion mode, an ion transfer tube temperature of 325°C, a normalized collision energy of 20-40-60 V cyclic collision energy, a primary mass spectrometer resolution of 60,000, a secondary mass spectrometer resolution of 7500, and data were collected in DDA mode.
[0032] As a sixth aspect of the present invention, the present invention also provides a method for screening the above-mentioned idiopathic asthenospermia markers, which comprises:
[0033] (1) Ten healthy men and 10 men with idiopathic asthenozoospermia were selected. The diagnostic criteria for idiopathic asthenozoospermia were 2 or more routine semen analyses, with a percentage of progressively motile sperm <32% and a sperm concentration >15×10 6 / mL, the percentage of normal morphological sperm> 4%, and men with azoospermia, reproductive system anatomical abnormalities, varicocele, infection, traumatic surgery, tumors, endocrine, hypertension and obesity and other systemic diseases, as well as abnormal chromosome karyotype and Y chromosome microdeletion were excluded.
[0034] (2) Pipette 100 μL of liquid sample into a 1.5 mL centrifuge tube, add 400 μL of extraction solution (acetonitrile: methanol = 1:1) containing 0.02 mg / mL internal standard (L-2-chlorophenylalanine), vortex mix for 30 seconds, extract by low-temperature ultrasound for 30 minutes (5°C, 40kHz), and place the sample at -20°C for 30 minutes. Centrifuge at 4°C, 13000g for 15 minutes, remove the supernatant, blow dry with nitrogen, re-dissolve with 100 μL of re-solution (acetonitrile: water = 1:1), extract by low-temperature ultrasound for 5 minutes (5°C, 40kHz), centrifuge at 4°C, 13000g for 10 minutes, and remove the supernatant into a vial with an inner insert for analysis.
[0035] (3) The sample solution was detected using ultra-high performance liquid chromatography tandem Fourier transform mass spectrometry (UHPLC-Q Exactive HF-X series mass spectrometry) to obtain fingerprints of 30 urine samples (the specific test conditions are described in the above section).
[0036] (4) Through data pre-processing, multivariate statistical analysis and screening of differential metabolites, the precise molecular weights of these differential metabolites are compared with the network database, and finally the metabolomics-based urine biomarker for early diagnosis of male idiopathic asthenospermia is obtained.
[0037] The implementation of the present invention has the following beneficial effects:
[0038] 1. The present invention provides urine biomarkers for the early diagnosis of male idiopathic asthenospermia. The urine biomarkers are one or more of 4'-phosphopantothenoylcysteine, 11-hydroxy-14,15-epoxyeicosatrienoic acid (11H-14,15-EETA), and 15-keto-prostaglandin F2a. The sensitivity and specificity of the markers are both greater than 0.9, and the area under the curve (AUC) is greater than or equal to 0.9, indicating that these three indicators have good predictive properties and can be used for the early diagnosis of male idiopathic asthenospermia.
[0039] 2. The present invention uses ultra-high performance liquid chromatography tandem mass spectrometry to perform metabolomics analysis on male urine, and models the response intensity data of the peaks of substances in all samples and performs discriminant analysis, thereby finding characteristic differential metabolites between normal men and men with idiopathic asthenospermia, and further analyzing the changes in the content of characteristic differential metabolites, and finding specific differential metabolites caused by idiopathic asthenospermia, i.e., early diagnostic molecular markers for idiopathic asthenospermia. The method provided by the present invention is non-invasive, convenient and fast, and can accurately reflect the differences in the metabolic spectrum between men with idiopathic asthenospermia and normal men, with high specificity. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 The principal component analysis (PCA) diagram of the two groups in positive and negative ion modes, A is positive ion and B is negative ion;
[0041] Figure 2 The OPLS DA score graphs of the two groups in positive and negative ion modes; A and B are negative ions, and C and D are positive ions;
[0042] Figure 3 Volcano plots of differential metabolites between the two groups in positive and negative ion modes (A) (B) and calorimetric expression plots of all differential metabolites (C);
[0043] Figure 4 The abundance of three urinary biomarkers in the two groups (A) and the corresponding ROC curves (B); 4'-Phosphopantothenoylcysteine represents 4'-phosphopantothenoylcysteine; 11H-14,15-EETA represents 11-hydroxy-14,15-epoxyeicosatrienoic acid; 15-Keto-prostaglandin F2a represents 15-keto-prostaglandin F2a. DETAILED DESCRIPTION
[0044] In order to make the purpose, technical solutions and advantages of the present invention more clear, the present invention will be further described below in conjunction with the accompanying drawings and specific embodiments.
[0045] Example 1 Collection and processing of clinical male urine samples
[0046] 1. This experiment selected 10 healthy men and 10 men with idiopathic asthenozoospermia. The diagnostic criteria for idiopathic asthenozoospermia were 2 or more routine semen analyses, with a percentage of forward-moving sperm <32% and a sperm concentration >15×10 6 / mL, the percentage of normal morphological sperm> 4%, and men with azoospermia, reproductive system anatomical abnormalities, varicocele, infection, traumatic surgery, tumors, endocrine, hypertension and obesity and other systemic diseases, as well as abnormal chromosome karyotype and Y chromosome microdeletion were excluded.
[0047] 2. Sample collection and pre-treatment
[0048] The subjects washed their hands with soap 2-3 times, wiped the penis, especially the glans and coronal sulcus, with 75% alcohol 2-3 times, retracted the foreskin as much as possible and avoided touching the inside of the collection container, and only collected midstream urine. The urine was collected using a large semen collection cup, divided into 1.5 ml EP tubes, centrifuged at 10000g for 10 minutes at 4°C, and the supernatant was frozen at 80°C.
[0049] Example 2 Analysis of Urine Metabolites in Male Patients with Idiopathic Asthenospermia by Ultra-High Performance Liquid Chromatography Tandem Mass Spectrometry
[0050] The 30 samples obtained in Example 1 were subjected to ultra-high performance liquid chromatography tandem mass spectrometry analysis, and the specific analysis conditions were as follows:
[0051] 1. Instruments and Equipment
[0052] Ultra-high performance liquid chromatography-tandem Fourier transform mass spectrometry (UHPLC-Q Exactive HF-X) was provided by Thermo Fisher Scientific; HSST3 chromatographic column (100 mm × 2.1 mm id, 1.8 μm) was provided by Waters Corporation of the United States; JXDC-20 nitrogen purge instrument was provided by Shanghai Jingxin Industrial Development Co., Ltd.; LNG-T88 desktop rapid centrifugal concentrator and dryer was provided by Taicang Huamei Biochemical Instrument Factory; Wonbio-96c high-throughput tissue disruptor was provided by Shanghai Wanbo Biotechnology Co., Ltd.; SBL-10DT ultrasonic cleaning machine 300W-10L was provided by Ningbo Xinzhi Biotechnology Co., Ltd.; Centrifuge 5430R high-speed refrigerated centrifuge was provided by Eppendorf of Germany; and NewClassic MF MS105DU electronic balance was provided by Mettler of Switzerland.
[0053] 2. Liquid chromatography conditions
[0054] Liquid chromatography conditions were as follows: 3 μL of sample was separated by HSS T3 column (100 mm × 2.1 mm id, 1.8 μm) and then entered mass spectrometry detection. Mobile phase A was 95% water + 5% acetonitrile (containing 0.1% formic acid), and mobile phase B was 47.5% acetonitrile + 47.5% isopropanol + 5% water (containing 0.1% formic acid). The flow rate was 0.40 mL / min, and the column temperature was 40°C.
[0055] 3. Mass spectrometry conditions:
[0056] The sample mass spectrometry signal was collected in positive and negative ion scanning mode, with a mass scanning range of 70-1050m / z. The sheath gas flow rate was 50psi, the auxiliary gas flow rate was 13psi, the auxiliary gas heating temperature was 425℃, the positive ion mode ion spray voltage was set to 3500V, the negative ion mode ion spray voltage was set to -3500V, the ion transfer tube temperature was 325℃, and the normalized collision energy was 20-40-60V cycle collision energy. The primary mass spectrometry resolution was 60000, the secondary mass spectrometry resolution was 7500, and the data were collected in DDA mode.
[0057] Example 3 Analysis of characteristic differential metabolites in urine of male patients with idiopathic asthenospermia
[0058] 1. Data preprocessing
[0059] After the computer is completed, the LC-MS raw data are imported into the metabolomics processing software Progenesis QI (Waters Corporation, Milford, USA) for baseline filtering, peak identification, integration, retention time correction, and peak alignment, and finally a data matrix of retention time, mass-to-charge ratio, and peak intensity is obtained. At the same time, the MS and MSMS mass spectrometry information is matched with the metabolic public database HMDB (http: / / www.hmdb.ca / ) and Metlin (https: / / metlin.scripps.edu / ) as well as the Meiji self-built library to obtain metabolite information.
[0060] After searching the database, the data matrix uses the 80% rule to remove missing values, that is, retaining variables with more than 80% non-zero values in at least one group of samples, and then filling in the missing values (filling the missing values with the minimum value in the original matrix). In order to reduce the errors caused by sample preparation and instrument instability, the response intensity of the sample mass spectrometer peak is normalized by the sum normalization method to obtain the normalized data matrix. At the same time, the variables with the relative standard deviation (RSD) of QC samples>30% are deleted, and log10 logarithm processing is performed to obtain the final data matrix for subsequent analysis.
[0061] 2. Multivariate statistical analysis
[0062] Secondly, the ropls package (Version 1.6.2) in R language was used to perform principal component analysis (PCA) and orthogonal least partial squares discriminant analysis (OPLS-DA) on the preprocessed data matrix, and 7 rounds of interactive validation were used to evaluate the stability of the model. Figure 3 and Figure 4 From the OPLS DA score graph, it can be seen that the diseased group and the control group can be completely distinguished, and the explanatory and predictive abilities of the model are good.
[0063] 3. Discover and analyze the characteristic differential metabolites
[0064] The selection of significantly different metabolites was based on the variable weight value (VIP) obtained by the OPLS-DA model and the student's t-test p value. Metabolites with VIP>1 and p<0.05 were significantly different metabolites. Finally, the receiver operating characteristic curve (ROC curve) analysis was used to evaluate the diagnostic ability of the biomarkers. The sensitivity and specificity of 4'-phosphopantothenoylcysteine, 11-hydroxy-14,15-epoxyeicosatrienoic acid (11H-14,15-EETA), and 15-keto-prostaglandin F2a were all greater than 0.9, and the area under the curve (AUC) was greater than or equal to 0.9, indicating that these three indicators have good predictive power, see Figure 4 . It shows that 4'-phosphopantothenoylcysteine, 11-hydroxy-14,15-epoxyeicosatrienoic acid (11H-14,15-EETA), and 15-keto-prostaglandin F2a can be used as urine biomarkers for the early diagnosis of male idiopathic asthenospermia.
[0065] The above is a preferred embodiment of the invention. It should be pointed out that a person skilled in the art can make several improvements and modifications without departing from the principle of the invention. These improvements and modifications are also considered to be within the scope of protection of the invention.
Claims
1. Use of urine biomarkers for idiopathic asthenospermia in the preparation of a kit for detecting idiopathic asthenospermia, characterized in that: The idiopathic asthenospermia urine biomarker is one or more of 4'-phosphopantenylated cysteine, 11-hydroxy-14,15-epoxyeicosatrienoic acid, and 15-keto-prostaglandin F2a.
2. Use of a reagent for detecting urine biomarkers of idiopathic asthenospermia in the preparation of a kit for detecting idiopathic asthenospermia, characterized in that: The idiopathic asthenospermia urine biomarker is one or more of 4'-phosphopantenylated cysteine, 11-hydroxy-14,15-epoxyeicosatrienoic acid, and 15-keto-prostaglandin F2a.
3. Use of urine biomarkers for idiopathic asthenospermia in the preparation or screening of drugs for treating idiopathic asthenospermia, characterized in that: The idiopathic asthenospermia urine biomarker is one or more of 4'-phosphopantenylated cysteine, 11-hydroxy-14,15-epoxyeicosatrienoic acid, and 15-keto-prostaglandin F2a.
4. A kit for detecting idiopathic asthenospermia, characterized in that: It includes reagents for detecting urine biomarkers of idiopathic asthenospermia, wherein the urine biomarkers of idiopathic asthenospermia are one or more of 4'-phosphopantenylic cysteine, 11-hydroxy-14,15-epoxyeicosatrienoic acid, and 15-keto-prostaglandin F2a.
5. A method for detecting urine biomarkers for idiopathic asthenospermia, characterized in that: The following steps are involved: The urine to be tested is extracted with an extraction solvent to obtain a test solution; The test solution is measured by liquid chromatography-mass spectrometry to obtain; Wherein, the extraction solvent is a mixture of acetonitrile and methanol, and the volume ratio of acetonitrile to methanol is 1:1 to 3:3; The chromatographic conditions of the liquid chromatography-mass spectrometry instrument include: a mixed solution of acetonitrile and water as mobile phase A, a mixture of acetonitrile, isopropanol and water as mobile phase B; the volume ratio of acetonitrile to water in mobile phase A is 90:10 to 99:1, and the volume ratio of acetonitrile, isopropanol and water in mobile phase B is 40:40:3 to 50:50:8; The mass spectrometry conditions of the liquid chromatography-mass spectrometry instrument include: a mass scanning range of m / z 70 to 1050; Wherein, the idiopathic asthenospermia urine biomarker is one or more of 4'-phosphopantenylated cysteine, 11-hydroxy-14,15-epoxyeicosatrienoic acid, and 15-keto-prostaglandin F2a.
6. The method for detecting urine biomarkers for idiopathic asthenospermia according to claim 5, characterized in that: In the step of extracting the urine to be tested with an extraction solvent to obtain a test solution, the urine to be tested and the extraction solvent are mixed in a volume ratio of 1:3 to 1:5, and ultrasonic extraction is performed at a frequency of 20kHz to 50kHz for 10min to 60min at 3°C to 10°C, and then the mixture is allowed to stand at -30°C to -10°C for 10min to 50min, and the supernatant is taken after centrifugation, and dried to obtain a solid phase, and the solid phase is dissolved with a complex solution, and ultrasonic extraction is performed at a frequency of 20kHz to 50kHz for 2min to 10min at 3°C to 10°C, and the supernatant is taken after centrifugation to obtain a test solution; The extraction solvent contains 0.01 mg / mL to 0.1 mg / mL of L-2-chlorophenylalanine; the reconstitution solution is a mixture of acetonitrile and methanol, and the volume ratio of acetonitrile to methanol is 1:1 to 3:
3.
7. The method for detecting urine biomarkers for idiopathic asthenospermia according to claim 5, characterized in that: The volume ratio of acetonitrile to water in the mobile phase A is 95:5, and the mobile phase A contains 0.1 vol% formic acid; The volume ratio of acetonitrile, isopropanol and water in the mobile phase B is 47.5:47.5:5; and the mobile phase B contains 0.1 vol% formic acid.
8. The method for detecting urine biomarkers for idiopathic asthenospermia according to claim 5, characterized in that: The chromatographic conditions of the liquid chromatography-mass spectrometer also include: The chromatographic column of the chromatographic-mass spectrometer uses octadecyl bonded silica gel as a filler, and its column length is 50 mm to 250 mm, the column diameter is 1 mm to 3 mm, and the particle size of the filler is 1.7 μm to 3 μm; The injection volume is 1 μL to 5 μL, the flow rate is 0.1 mL / min to 1 mL / min, and the column temperature is 30°C to 45°C.
9. The method for detecting urine biomarkers for idiopathic asthenospermia according to claim 5, characterized in that: The chromatographic conditions of the liquid chromatography-mass spectrometer also include: Positive and negative ion scanning modes were adopted, with a sheath gas flow rate of 30psi~80psi, an auxiliary gas flow rate of 10psi~20psi, an auxiliary gas heating temperature of 400℃~450℃, an ion spray voltage of 3000V~4000V in positive ion mode, an ion spray voltage of -4000V~-3000V in negative ion mode, an ion transfer tube temperature of 320℃~350℃, a normalized collision energy of 20-40-60V cyclic collision energy, a primary mass spectrometer resolution of 50000~70000, a secondary mass spectrometer resolution of 6000~8000, and DDA mode was adopted to collect data.
10. The method for detecting urine biomarkers for idiopathic asthenospermia according to claim 5, characterized in that: The chromatographic conditions of the liquid chromatography-mass spectrometer also include: The chromatographic column of the chromatography-mass spectrometry instrument is a Waters Xselect HSS T3 chromatographic column, with a column length of 100 mm, a column diameter of 2.1 mm, and a particle size of the filling phase of 1.8 μm; The injection volume was 3 μL, the flow rate was 0.4 mL / min, and the column temperature was 40 °C; The chromatographic conditions of the liquid chromatography-mass spectrometer also include: Positive and negative ion scanning modes were adopted, with a sheath gas flow rate of 50 psi, an auxiliary gas flow rate of 13 psi, an auxiliary gas heating temperature of 425°C, an ion spray voltage of 3500 V in positive ion mode, an ion spray voltage of -3500 V in negative ion mode, an ion transfer tube temperature of 325°C, a normalized collision energy of 20-40-60 V cyclic collision energy, a primary mass spectrometer resolution of 60,000, a secondary mass spectrometer resolution of 7500, and data were collected in DDA mode.
